Quick Answer
ABBOTT LABORATORIES reported Stockholders Equity of $52.13 billion for fiscal year 2025.
ABBOTT LABORATORIES Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $52.13B | +9.4% |
| 2024 | $47.66B | +23.5% |
| 2023 | $38.60B | +5.2% |
| 2022 | $36.69B | +2.5% |
| 2021 | $35.80B | +9.2% |
| 2020 | $32.78B | +5.5% |
| 2019 | $31.09B | +1.8% |
| 2018 | $30.52B | -1.2% |
| 2017 | $30.90B | +50.4% |
| 2016 | $20.54B | -3.2% |
| 2015 | $21.21B | -1.5% |
| 2014 | $21.53B | -14.5% |
| 2013 | $25.17B | -5.8% |
| 2012 | $26.72B | +9.3% |
| 2011 | $24.44B | +7.8% |
| 2010 | $22.68B | -2.0% |
| 2009 | $23.14B | +32.4% |
| 2008 | $17.48B | -1.7% |
| 2007 | $17.78B | +26.5% |
| 2006 | $14.05B | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.95B | +28.0% | +0.8% |
| June 30, 2025 | $50.56B | +28.6% | +3.6% |
| March 31, 2025 | $48.81B | +25.8% | +2.4% |
| December 31, 2024 | $47.66B | +23.5% | +19.8% |
| September 30, 2024 | $39.80B | +6.2% | +1.2% |
| June 30, 2024 | $39.32B | +5.8% | +1.3% |
| March 31, 2024 | $38.81B | +4.9% | +0.5% |
| December 31, 2023 | $38.60B | +5.2% | +3.0% |
- ABBOTT LABORATORIES showed an increase of +9.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2006–2025 period, ABBOTT LABORATORIES’s stockholders equity has grown by 270.9% (from $14.05 billion to $52.13 billion).
- The most recent figure is from ABBOTT LABORATORIES’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: